Apimeds Pharmaceuticals US, Inc. filings document a Delaware clinical-stage biopharmaceutical issuer with common stock registered on NYSE American under APUS and emerging growth company status. Recent 8-K and 12b-25 records cover material definitive agreements, governance and executive changes, shareholder written-consent and voting matters, preferred stock and convertible-note conversion disclosures, and capital-structure matters.
The filing record also includes notices tied to delayed Form 10-K reporting and NYSE American continued-listing compliance, along with disclosures related to settlement agreements and merger-related governance matters. Periodic and event filings frame Apimeds' operating and financial results, risk factors, and clinical or regulatory disclosures for the Apitox program.
Apimeds Pharmaceuticals US, Inc. (APUS) reports that Co-Chief Executive Officer Vin Menon directly holds Series A Convertible Preferred Stock representing 484,775 shares of common stock issuable upon conversion, as adjusted for the 1-for-10 reverse stock split effective July 23, 2026. The preferred stock is not convertible at his option; it automatically converts on the third business day following the later of effectiveness of stockholder approval of the conversion under NYSE American rules and NYSE American’s approval of the company’s new listing application. Each preferred share converts into 20 common shares, subject to adjustment, with no additional consideration payable.
Apimeds Pharmaceuticals US, Inc., through its wholly owned subsidiary MindWave Innovations Inc., entered a two-year agreement with BlockAssure effective October 4, 2026, for MindWave to build, deploy, operate and maintain AssureChain, a dedicated MindChain subnet for insurance and reinsurance workflows. MindWave is BlockAssure’s exclusive blockchain provider for AssureChain during the agreement. Development is planned over four quarters against agreed milestones, and BlockAssure will acceptance-test each module; hosting and ongoing operations begin after the first module is accepted.
Compensation includes a fixed development fee payable in quarterly installments, operating and maintenance fees to be agreed, and an allocation equal to 20% of AssureCoin’s total supply, delivered when the token is created. Anti-dilution terms maintain MindWave’s 20% share if more AssureCoin is issued during the agreement or for two years afterward. The agreement renews automatically for one-year periods unless either party gives 90 days’ notice of non-renewal.
Apimeds Pharmaceuticals US, Inc. reported that Interim Chief Financial Officer Erick Frim resigned effective immediately on September 29, 2026, and that its board appointed Eric Sherb as Chief Financial Officer effective October 1, 2026. Sherb will serve as principal financial officer and principal accounting officer. The company said Frim’s resignation was not due to a disagreement over company operations, policies or practices.
Sherb, a Certified Public Accountant with over 18 years of capital-markets experience, will receive a base salary of $60,000 per year under an Executive Employment Agreement effective October 1, 2026. Since February 2026, he had served as fractional Chief Financial Officer of the company’s wholly owned subsidiary, MindWave Innovations Inc., through EMS Consulting Services; that engagement will end in connection with his appointment. Any future equity awards under the company’s equity incentive plan are outside the stated compensation.
Apimeds Pharmaceuticals US, Inc. (APUS) reported that its wholly owned subsidiary, MindWave Innovations, entered two 12-month technology services agreements: one with AQUAE Holdings for AQUAEChain and one with Flash Sports & Media Holdings for FlashChain.
Under the AQUAE agreement, MindWave will deploy MindChain for the issuance, verification, transfer and retirement of ALCI Credits. Consideration includes service fees and an allocation equal to 20% of total ALCI Credits issued and outstanding on the AQUAEChain network, calculated at the end of each quarter using the MindChain issuance ledger. After the initial term, the parties anticipate a five-year services arrangement, subject to mutual agreement and definitive documentation.
For FlashChain, MindWave will build and operate a dedicated subnet for tracking broadcasting rights, video assets and match ticket inventory. Consideration includes FLZH common shares, an allocation equal to 20% of total FLASH TOKEN supply, and an annual maintenance fee equal to 50% of applicable contract consideration. Deliverables are subject to FLZH acceptance testing; support may be renewed annually after the initial term.
Apimeds Pharmaceuticals US, Inc. (APUS) effected a 1-for-10 reverse stock split of its issued and outstanding common stock, effective at 12:01 a.m. Eastern Time on July 24, 2026. Immediately before the split, 15,091,180 common shares were issued and outstanding; immediately after, 1,509,118 were issued and outstanding. The company subsequently issued 33,506 additional shares to accommodate rounding up fractional shares at the beneficial holder level through the Depository Trust Company. No fractional shares were issued; holders otherwise entitled to a fraction received one whole share. The amendment also reduced common stock par value from $0.01 to $0.001 per share. Authorized common and preferred shares remained at 100,000,000 and 10,000,000, respectively. Common stock began split-adjusted trading on NYSE American under APUS on July 24, 2026.
Apimeds Pharmaceuticals US, Inc. (APUS) entered into a First Amendment to its Confidential Settlement and Mutual Release Agreement on September 10, 2026, modifying how its board of directors is structured. During the interim period before the Preferred Stock Conversion, the board will consist solely of Elona Kogan, Carol O’Donnell, Dr. Bennett Weintraub, and Sungjoon Chae, and none of these directors may be removed without the written consent of Dr. Vin Menon and the Inscobee Parties.
After this interim period, the board is set at seven members: four independent directors nominated by MindWave, two directors nominated by Menon (including Menon), and Sungjoon Chae. On September 10, 2026, the board appointed Sungjoon Chae, already Co-Chief Executive Officer since May 2026, as a director; the company states there are no related party transactions or family relationships involving him, and his director compensation terms will be disclosed once finalized.
Apimeds Pharmaceuticals US, Inc. (APUS) entered into an Assignment and Transfer Agreement with FreeT Inc. on August 19, 2026 to acquire certain Apitox-related rights previously held by FreeT under a 2015 agreement. The Assigned Rights include 100% of rights to the Apitox market for Korean medicine clinics in Korea, a 25% royalty entitlement on economic proceeds from Apitox development, licensing, sale or other commercialization in the United States, and a 25% revenue participation right on net proceeds from overseas rights agreements. Apimeds also receives specified information and data/technology-related contractual benefits, while expressly not acquiring underlying Apitox intellectual property or any global rights not held by FreeT. Apimeds assumes only post-effective-date obligations directly tied to exercising these rights, and FreeT indicates it will use commercially reasonable efforts to support future global Apitox rights transactions, subject to separate definitive agreements. The agreement is governed by the laws of the Republic of Korea with exclusive jurisdiction in the Seoul Central District Court.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $55.2 million for the six months ended June 30 2026, compared with $3.1 million a year earlier. Results reflect its dual structure: a clinical-stage BioBusiness developing APITOX for osteoarthritis pain and a Digital Asset segment holding Bitcoin, Tether and NILA tokens.
Digital assets were carried at $116.7 million, or 89% of total assets, and generated an unrealized loss of $35.3 million as prices declined, partially offset by realized and trading gains and $0.3 million of digital asset yield income. Operating expenses rose sharply, including $16.6 million of general and administrative costs with an $8.1 million non-cash advisory share charge and higher legal, advisory and public-company expenses.
Liquidity is strained: cash and cash equivalents were $278,371 with $8.0 million in restricted cash, while $5.0 million of short-term notes and a $10.9 million senior secured convertible note were current obligations. The company disclosed substantial doubt about its ability to continue as a going concern, is in discussions to extend or restructure debt, and faces NYSE American continued-listing risk after prior filing delays. A 1‑for‑10 reverse stock split became effective July 24 2026.
Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as Chief Scientific Officer, effective August 5, 2026. In this role, he will lead scientific, clinical, and regulatory development of the company’s APITOX program, including research and development, clinical strategy, and regulatory engagement.
The company states that Dr. Kim has been closely associated with APITOX for many years and has extensive scientific, technical, and regulatory expertise. His appointment is described as providing leadership continuity and supporting the company’s long-term strategy to advance APITOX through the regulatory process and toward commercialization.